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Objectives: The World Health Organization recommends that all children admitted with severe
malnutrition should routinely receive parenteral ampicillin and gentamicin; despite this, mortality
remains high. Since this population group is at risk of altered volume of distribution, we aimed to
study the population pharmacokinetics of once daily gentamicin (7.5 mg/kg) in children with severe
malnutrition and to evaluate clinical factors affecting pharmacokinetic parameters.
Methods: Thirty-four children aged 0.5–10 years were studied. One hundred and thirty-two gentamicin
concentrations (median of four per patient), drawn 0.4–24.6 h after administration of the intramuscular
dose, were analysed. The data were fitted by a two-compartment model using the population package
NONMEMw.
Results: Gentamicin was rapidly absorbed and all concentrations measured within the first 2 h after
administration were >8 mg/L (indicating that satisfactory peak concentrations were achieved). Ninety-
eight percent of samples measured more than 20 h after the dose were <1 mg/L. The best model
included weight, and it was found that high base deficit, high creatinine concentration and low temp-
erature (all markers of hypovolaemic shock) reduced clearance (CL/F). Weight influenced volume of the
central (V1/F) and peripheral (V2/F) compartments, and high base deficit reduced V2/F and intercom-
partmental CL (Q/F). Interindividual variability in CL was 26%, in V1/F 33% and in V2/F and Q/F was
52%. Individual estimates of CL/F ranged from 0.02 to 0.16 (median 0.10) L/h/kg and those of Vss/F
from 0.26 to 1.31 (median 0.67) L/kg. Initial half-lives had a median of 1.4 h and elimination half-lives
and a median of 14.9 h. Excessive concentrations were observed in one patient who had signs of renal
impairment and shock.
Conclusions: Although a daily dose of 7.5 mg/kg achieves satisfactory gentamicin concentrations in
the majority of patients, patients with renal impairment and shock may be at risk of accumulation with
24 hourly dosing. Further studies of gentamicin pharmacokinetics in this group are now needed to
inform future international guideline recommendations.
Keywords: antimicrobial therapy, population pharmacokinetics, kwashiorkor, marasmus, Africa, parenteral
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
*Corresponding author. Tel: þ 254-415-22063; Fax: þ254-415-22390; E-mail: kmaitland@kilifi.kemri-wellcome.org
Journal of Antimicrobial Chemotherapy (2007) 59, 681–689
doi:10.1093/jac/dkl561
Advance Access publication 8 March 2007
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
681
# The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University
Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its
entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Introduction
Globally, severe malnutrition is a common cause of paediatric
admission to hospital in less well-developed countries. Children
with severe malnutrition are more susceptible to infection;
proven invasive bacterial disease is a common complication,
particularly among those dying.1,2,32 From the limited number
of studies detailing the spectrum of infecting pathogens,
both Gram-positive and Gram-negative organisms appear to
be important.3 – 6 Principal isolates include Streptococcus
pneumoniae, Escherichia coli and non-typhoid salmonellae,
Haemophilus influenzae and Staphylococcus aureus.7
Consequently, the WHO recommends that all children admitted
with severe malnutrition should routinely receive parenteral
ampicillin and gentamicin.1 Examination of in-house data has
shown that confirmed bacteraemia occurs in 12% of all severe
malnutrition admissions and complicates 26% of case fatalities:
52% of these deaths occurring within 48 h of admission. This
high fatality is striking given that in vitro antibiotic suscepti-
bility testing indicates that up to 85%7 of organisms are fully
susceptible to the antimicrobial regimen recommended by
WHO,1 which is prescribed on admission to all cases of severe
malnutrition.7 A previous study examining susceptibility patterns
among Gram-negative bacilli reported lower levels of isolates
fully susceptible to gentamicin (76%); however, in cases with
malnutrition, gentamicin resistance was not found to be associ-
ated with mortality.8 These deaths, on adequate treatment, call
for an evaluation of the additional risk factors associated
with in-hospital death, including an in-depth assessment of the
pharmacokinetics of gentamicin in this patient group.
Gentamicin, an aminoglycoside, remains the mainstay of
treatment for Gram-negative sepsis, as it is cheap and widely
available. It demonstrates a concentration-dependent bactericidal
activity against a broad spectrum of Gram-negative bacilli,
aerobic and facultative anaerobes and also has in vitro activity
against Haemophilus spp. and methicillin-susceptible S. aureus,
especially when used as part of a combination therapy.9 The use
of ‘once daily’ dosing of gentamicin is increasingly favoured as
it results in high peak concentrations (increasing antibacterial
efficacy) and the prolonged drug-free interval reduces the risk of
drug toxicity. The volume of distribution is the most important
parameter determining the peak concentration and is closely
related to the extracellular fluid volume because of the low level
of protein binding and high solubility in water.9 The volume
of distribution is increased in oedematous states, burns (or exten-
sive skin desquamation) and with capillary leak in severe
infection. Children with severe malnutrition may have all three
complications: oedema, wide spread dermatosis and shock due
to bacterial infection. The high fatality of children on treatment




The study was undertaken at the KEMRI Centre for Geographic
Medicine Research (Coast) at Kilifi District Hospital, Kenya.
Parental consent was obtained for all subjects. The KEMRI
scientific steering and national ethics research committees
approved the study. The aim was to examine the
pharmacokinetics of intramuscular gentamicin in children
admitted with severe malnutrition who were routinely managed
according to the WHO guidelines, including the provision of
nutritional support and empirical antibiotic therapy.
Children over 6 months of age whose parents gave consent to
enter the study and who had one of the following anthropometric
criteria for severe malnutrition were eligible for inclusion in the
study: weight for height percentile ,70%; bilateral oedema
(of kwashiorkor) or mid-upper arm circumference (MUAC)
,11.0 cm (if .12 months of age). Additional indicators of
severe malnutrition, including visible severe wasting and typical
hair and skin changes, were used when anthropometric criteria
were not available. Children admitted with a plasma creatinine
concentration .160 mmol/L (twice the upper limit of normal for
children more than 1 year old) were excluded from the study.
Children were treated according to the standard WHO man-
agement guidelines for severe malnutrition,10,11 which includes
resuscitation procedures where appropriate, the judicious use of
intravenous (iv) fluids, nasogastric feeding and vitamin and
mineral supplementation. Antimicrobial treatment included intra-
muscular gentamicin (7.5 mg/kg once daily) for 7 days and iv
ampicillin (50 mg/kg four times daily) for 48 h. At this stage, a
decision was made to change to oral amoxicillin (15 mg/kg
three times daily) if the child was clinically improving and
blood cultures were negative. If the child had deteriorated, iv
chloramphenicol (25 mg/kg three times daily) was added for 5
days. In addition, all children were treated with mebendazole
(100 mg twice daily) for 3 days. A single batch of gentamicin,
obtained from a national supplier (MEDS, Nairobi, Kenya) with
appropriate quality control certification, was used for this study.
The doses were prepared and administered by a member of the
study team.
Gentamicin sampling and analysis
Patients were randomized on admission, using a computer-
generated randomization list, into three groups for gentamicin
sampling: Group A children had samples taken after the first
dose of gentamicin (day 1); Group B children on day 3; and
Group C children on day 5. In order to maximize the infor-
mation and at the same time to minimize the blood sampling
frequency per child, within each group, patients were allocated
to one of three sampling schedules: Subgroup 1 at 0, 0.5, 8
and 24 h; Subgroup 2 at 0, 2, 12 and 24 h; and Subgroup 3 at 0,
4, 16 and 24 h. At each time point, a sample of 0.5 mL of
venous blood was collected into a lithium heparin tube, spun,
plasma removed and stored in Cryovials at 2208C for later
batch processing.
Plasma gentamicin concentrations were determined using the
Abbott TDxFLxw fluorescence polarization immunoassay (Abbott
Laboratories, Diagnostics Division, Abbott Park, IL, USA). The
target (range) concentrations for low (L), medium (M) and high
(H) quality control (QC) samples were 1.0 (0.85–1.15), 4.0
(3.60–4.40) and 8.0 (7.20–8.80) mg/L, respectively. The nominal
concentrations for the gentamicin calibrators were 0, 0.5, 1.5, 3.0,
6.0 and 10.0 mg/L. The manufacturer supplied the samples
for calibration and QC samples. The method is reported to have
a sensitivity of 0.27 mg/L and concentrations .10 mg/L were
diluted before analysis. The assay coefficients of variation were
6.8% (n ¼ 6), 6.3% (n ¼ 7) and 4.7% (n ¼ 5) for the LQC,




Details of clinical features, blood sampling times, results and
gentamicin dosage history and concentration measurements,
including all dosage and sampling times, were entered into
an Excelw spreadsheet. Pharmacokinetic parameter estimates
were obtained using NONMEMw (Version V, GloboMax
LLC, Hanover, MD, USA), with a Visual FORTRAN Version
6.0 compiler (DIGITALTM, Digital Equipment Corporation,
Maynard, MA, USA). Further analyses of the NONMEM output
results were conducted using Xpose (Version 3.1)12 and
SPLUS6w (Insightful Corporation, Seattle, WA, USA).
Data were analysed using both one- and two-compartment
models with the First Order Conditional Estimation with
Interaction algorithm. Interindividual variability was assumed to
be log-normally distributed and residual error was initially
examined using a combined (additive and proportional) error
structure. Individual estimates of clearance/bioavailability
(CL/F), volume of distribution/F, etc. and individual predicted
concentrations were also obtained.
The potential influence of clinical characteristics on the phar-
macokinetics of gentamicin was first examined graphically and
then generalized additive modelling (GAM) was undertaken
using the Xpose package.12 These screening approaches ident-
ified factors that should be explored further using NONMEMw
and were repeated as the covariate model was developed.
Potential covariates were added to and subtracted from the
model in a stepwise fashion and the impact of order of addition
was also investigated. A value for length was missing from one
patient; therefore, the extrapolated value from a linear regression
of length versus age (correlation coefficient 0.85) was used to
estimate the missing length. This value was imputed into the
data set and used in the covariate analysis. Statistical comparison
of models was based on a x2 test with P , 0.05 significant [fall
of 3.84 in the objective function value (OFV)].
Results
Participants and admission clinical characteristics
The study period was January–March 2005. Thirty-four children
with severe malnutrition, as defined by the WHO, were entered
into the study. A further 12 patients satisfied the anthropo-
morphic entrance criteria but either refused or died before
consent or had a serum creatinine .160 mmol/L. A summary of
the clinical characteristics of all the patients who were screened
is presented in Table 1 and the characteristics of the patients
included in the study are detailed in Table 2. The mean (SD)
age of the study patients was 3.1 years (+2.2 years) and 62%
were male. Marasmic malnutrition (with no oedema) was more
common, 62% (21/34); 94% (17/18) of marasmic children had a
weight for height Z score (WHZ) more than 3 SD below the
mean. Thirty-eight percent (13/34) had oedematous malnutrition
(kwashiorkor). Overall, the mean WHZ (+SD) was 23.3 + 1.3,
but was significantly lower in those presenting with marasmus
(mean WHZ 23.67 + 1.1) than in those with oedematous mal-
nutrition (mean WHZ 22.42 + 1.8); P ¼ 0.03. In the group
with kwashiorkor, a significantly greater proportion had MUAC
scores ,11 cm (8/13; 62%), dermatosis and hair changes
associated with malnutrition (11/13; 85%) than the marasmic
group.
None of the study participants had a positive blood culture;
however, one patient had a urinary tract infection (E. coli). In
the group of patients who refused consent or were ineligible, a
higher proportion were noted to have bacteraemia (4/12; 33%)
and Plasmodium falciparum malaria (7/12; 58%). HIV testing,
after informed consent, was offered to all patients in the study
group; eight (24%) parents refused consent. Of those that were
tested, 32% were found to be HIV antibody positive (8/25),
including 2 infants ,18 months (classified by WHO as HIV
exposed). This compares with 8% in unselected children tested
at Kilifi13 and recent estimates, in all cases with severe malnu-
trition, of 27% (K. Maitland, unpublished results). Nine patients
(26%) had detectable levels of malaria parasites on admission.






Age (years) 3.1 + 2.2 1.7 + 0.9
Male (%) 62 75
WHZ 23.3 + 1.3 23.1 + 1.2
MUAC ,11 cm (%) 56 41
Oedema (%) 38 17
Admission temperature (8C) 37.6 + 1.2 38.2 + 1.0
Admission creatinine (mmol/L) 43 + 22.7 68 + 39.7
P. falciparum positive (%) 26 58
Urine culture positive 1/27 0/5
Culture-proven bacteraemia (%) 0 33a
HIV positive 8/25 (32%) none tested
Mortality (%) 12 25
Values are means+SD or percentages.
aS. pneumoniae, b-haemolytic streptococci, Shigella sp.
Table 2. Clinical characteristics of the patient group at the start of
gentamicin therapy
Variable Number Median Minimum Maximum
Age (years) 34 2.4 0.5 9.9
Weight (kg) 34 7.85 4.60 13.70
Length (cm) 33 75.5 61.7 126.0
WHZ score 28 23.2 26.5 21.0
Temperature (8C) 34 37.3 35.2 39.8
Sodium (mmol/L) 34 136 124 144
Potassium (mmol/L) 34 3.6 2.3 4.8
Creatinine (mmol/L) 34 40 17 117
Glucose (mmol/L) 34 4.2 0.7 11.1
Haemoglobin (g/dL) 34 8.4 3.7 11.0
White cell count
(109/L)
34 11.5 1.6 55.7
Platelet count
(109/L)
34 320 17 836
pH 32 7.358 7.094 7.455
PaCO2 (kPa) 32 4.62 2.86 17.20
Bicarbonate (mmol/L) 32 19.5 7.4 26.6
Base deficit (mmol/L) 32 5.2 24.9 22.6
Gentamicin pharmacokinetics in malnutrition
683
Two patients were transfused on admission for severe anaemia
(haemoglobin ,4 g/dL); one child’s condition was complicated
by malaria and the other child presented with features of sickle
cell disease. Five patients had a capillary refill time (CRT; a
bedside test that is used to examine perfusion) of .3 s, but only
one patient was treated for shock with iv fluids in accordance
with the WHO recommendations—Patient 34 who later died.
Four patients received iv fluids during the study period for other
clinical indications (hypoglycaemia, hypokalaemia and a sickle
cell crisis). Overall, four (12%) children died before discharge.
One died 28 h after admission before HIV screening and the
other three within 1–3 weeks of admission. Of these late deaths,
two were HIV positive and one had severe cerebral palsy. The
excluded patients had a higher mortality rate (3/12; 25%), and
all three patients died within 36 h of admission.
Gentamicin assay data
Gentamicin concentration data were available from 34 infants
and children; 4 from each subgroup, except A3 and B1 which
each contained 3 infants. A total of 132 gentamicin concen-
tration measurements, ranging from below the limit of quantifi-
cation to 42.5 mg/L, were available for analysis. Sample times
ranged from 0.4 to 24.6 h after the dose (median 12 h) and there
were three to four (median of four) samples per patient. Eleven
samples were taken within the first hour after administration (an
estimate of the peak concentration) and 35 were taken more than
16 h after the dose (to assess the trough levels). Thirty-two
measurements were below the limit of quantification; 12 of
these samples represented baseline measurements before the first
dose of gentamicin was administered and the remaining 20
samples were all taken more than 15 h after the previous dose.
As illustrated in Figure 1, gentamicin was absorbed rapidly
with peak concentrations being observed at the post-first dose
sampling time in each patient. All nine concentrations measured
within the first 40 min were .15 mg/L and of the 17 samples
taken within the first 2 h after the dose, all were .8 mg/L
and 13 (76%) were .12 mg/L. Forty-seven samples were
taken more than 20 h after the dose, of which 38 (80%) were
,0.5 mg/L (including 17 below the limit of quantification) and
46 (98%) were ,1 mg/L. One patient (Patient 34, Figure 1) had
consistently high concentration measurements throughout the
dosage interval and a trough of 5.5 mg/L.
Pharmacokinetic analysis
Concentration measurements below the limit of quantification
were excluded from the population pharmacokinetic analysis but
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Figure 1. Plot of gentamicin concentrations versus time after dose in 34 infants and children with malnutrition who received 7.5 mg/kg daily by
intramuscular injection. The numbers on the plot correspond to individual patients and the dotted lines indicate the profiles in each patient.
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included in the data file as ‘other’ events, which allowed clinical
data measured at these times to be included in the file.
A two-compartment model best described the concentration
data, as illustrated by the biexponential decline shown in
Figure 1. Since the maximum concentration was observed at the
first sampling point in all cases, it was not possible to estimate
the absorption rate constant. Fixing the absorption rate constant
to a range of values offered no advantage in fitting the data, but
increased model instability.
Interindividual variabilities in intercompartmental clearance
(Q/F) and volume of the peripheral compartment (V2/F) were
highly correlated and a single parameter proved sufficient to
describe both. Covariance was allowed between interindividual
variabilities in CL/F, volume of the central compartment (V1/F)
and the combined Q/V2 variability. Residual error was adequately
described by a proportional error model.
Graphical analysis identified possible relationships between
clearance and weight, length, age, temperature, base deficit,
bicarbonate concentration and serum creatinine concentration, as
illustrated in Figure 2. Both V1/F and V2/F appeared to be
related to weight, age and length. These size factors were highly
correlated with each other, with correlation coefficients ranging
from 0.81 to 0.85. Since base deficit and bicarbonate concen-
tration were also highly correlated (correlation coefficient, 0.89),
only the results obtained using base deficit are presented.
Patient 34 had a particularly low CL/F (0.02 L/h/kg, com-
pared with the group median of 0.1 L/h/kg), which resulted in
very high concentrations and was associated with derangement
of several clinical factors (Figure 2). This patient had hypovolae-
mic shock, renal impairment and probable sepsis characterized
by hypothermia, hyponatraemia, an elevated serum creatinine
concentration (109 mmol/L) and a metabolic acidosis. He
received iv fluid resuscitation but deteriorated and died within
36 h of admission. His creatinine measurement before death had
risen to 177 mmol/L.
GAM identified age, weight and base deficit as the best pre-
dictors of gentamicin clearance. No trends were identified with
the following biochemical and haematological measurements:
serum potassium; serum glucose; haemoglobin concentration,
white cell count; and platelet concentration. Other factors that
were retained for further consideration were presence of oedema;
CRT; serum sodium concentration; and use of iv fluids.
CL/F was related to weight using both a linear model and
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Figure 2. Scatterplots showing potential relationships between individual estimates of gentamicin clearance and a range of clinical factors. The numbers
represent individual patients and the solid lines indicate a smooth through the data. CL, clearance/F; TEMP, temperature (8C); HCO3, bicarbonate
concentration (mmol/L); AGE, age (days); WT, body weight (kg). Note: base excess is the negative value of base deficit.
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suggested that the linear model was adequate and since the
allometric approach also gave a slightly higher OFV, it was not
considered further. The addition of creatinine to the weight
corrected CL/F model provided an improvement in fit but length
did not. A small influence of age was initially identified, but
was no longer significant at later stages of the analysis.
The initial clearance model included weight, serum creatinine
concentration, base deficit and temperature ,368C. Examination
of scatterplots and a further GAM analysis at this stage ident-
ified CRT as a potential additional covariate on all parameters
and base deficit and oedema on V2/F and Q/F. Although the
addition of these clinical factors improved the OFV values,
statistical significance varied according to the order of inclusion,
there was often little or no reduction in the interindividual
variability and some parameter estimates were poorly defined
(relative standard errors .40%).
Table 3 summarizes the principal models that were tested. The
final model contained weight, temperature, serum creatinine con-
centration and base deficit as factors influencing clearance. Base
deficit also influenced V2/F and Q/F. However, the effects of
Table 3. Summary of the principal models tested during development of the covariate model
No. Clearance/F model V2/F model Q/F model cvCL cvV1 cvV2,Q OFV DOFV c.f. model
1 43 32 64 217.9
2 creatinine 37 33 60 227.1 9.2 1
3 creatinine, BD 31 31 57 239.4 12.3 2
4 creatinine, BD, temp 29 32 57 246.1 6.7 3
5 creatinine, BD, temp BD 26 32 51 250.5 4.4 4
6 creatinine, BD, temp BD 26 33 51 253.9 7.8 4
7 creatinine, BD, temp BD BD 26 33 52 2 57.9 4.0 6
8 BD, temp BD BD 29 32 52 252.7 25.2 7
9 creatinine, BD BD BD 28 33 53 251.7 26.2 7
10 creatinine, temp BD BD 35 32 65 235.3 222.6 7
V2/F, volume of the peripheral compartment; Q/F, intercompartmental clearance; cvCL, interindividual variability in clearance/F; cvV1, interindividual
variability in volume of the central compartment/F; cvV2,Q, interindividual variability in V2/F and Q/F; OFV, objective function value; DOFV, change in
OFV, .3.84 is significant at P , 0.05 and .6.64 is significant at P , 0.01; c.f. model, compared with model number; BD, base deficit; temp, temperature
(8C). Bold font indicates final model (no. 7).
Table 4. Population and individual gentamicin pharmacokinetic parameter estimates from Model 7
Parameter and model Parameter estimate %RSE
CL/F ¼ CLB  [1 2 uBD (BD 2 5.2)]  (1 2 uTP)  (Cr/33)uCR




IIVCL (%) 26 34
V1/F (L/kg) 0.254 8.8
IIVV1 (%) 33 33
V2/F ¼ V2B [1 2 uBD(BD 2 5.2)]
V2B (L/kg) 0.406 14
uBD 0.0450 24
IIVV2 (%) 52 40
Q/F ¼ QB  [1 2 uBD(BD 2 5.2)]
QB (L/kg) 0.0239 12
uBD 0.0512 14
IIVQ (%) 52 40
Residual error (%) 13.8 9.1
CL/F, clearance/bioavailability; CLB, baseline clearance for a patient with a base deficit (BD) of 5.2, serum creatinine concentration (Cr) 33 mmol/L and
temperature (TP) 368C; u, parameter estimate; V1/F, volume of the central compartment/bioavailability; V2/F, volume of the peripheral compartment/
bioavailability; Q/F, intercompartmental clearance/bioavailability; %RSE, percentage relative standard error; IIV, interindividual variability expressed as
% coefficient of variation.
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creatinine concentration and temperature on clearance and base
deficit on Q/F failed to achieve statistical significance at P , 0.01.
Population parameter estimates obtained with the final model are
presented in Table 4 and measured versus population- and
individual-predicted concentration measurements are presented
in Figure 3. Individual CL/F estimates ranged from 0.02 to
0.16 L/h/kg (median 0.10 L/h/kg) and individual estimates of
Vss/F (V1/FþV2/F) ranged from 0.26 to 1.31 L/kg (median
0.67 L/kg). These values translated to initial half-lives with a
median (range) of 1.4 (0.8–5.0) h and terminal half-lives of 14.9
(13.3–16.4) h.
Discussion
This study has demonstrated that a single daily intramuscular
dose of 7.5 mg/kg gentamicin is rapidly absorbed and consist-
ently achieves peak concentrations .8 mg/L in infants and chil-
dren with malnutrition. Trough concentrations were typically
,0.5 mg/L, indicating a low potential for toxicity, although
excessive accumulation was observed in one critically ill patient
whose renal function deteriorated rapidly before death. A popu-
lation pharmacokinetic analysis confirmed the influence of
weight and renal function on gentamicin handling and addition-
ally identified that indicators of sepsis and shock, such as low
temperature and high base deficit, were associated with a
reduced clearance.
This study is the first to attempt to provide the data that
confirm the safety and likely efficacy (extrapolated from the
pharmacokinetic data) of the current WHO antimicrobial guide-
lines in severely malnourished children. As the routine monitor-
ing of gentamicin levels is not possible at most hospitals in
Africa, these data are reassuring, particularly for children with
uncomplicated presentations. A much larger study, conducted in
over 300 Bangladeshi children hospitalized with malnutrition,
pneumonia and diarrhoea, was recently published by Khan
et al.15 They found no significant differences in efficacy or
toxicity when 5 mg/kg gentamicin was given as a single daily
intramuscular dose or spilt into three, although there was a trend
towards better efficacy and lower toxicity with the single daily
dose. However, they used a gentamicin dose that is lower than is
currently recommended. Furthermore, ceftriaxone, which is not
currently recommended in the WHO guidelines, was used in
combination with gentamicin. This antibiotic is not widely avail-
able in resource-poor countries and, in the absence of data to
support its utility, is precluded from general recommendations
on the basis of cost.
The overall mortality in our study was 12%, but 25% in
excluded patients. One of the limitations of this study was that
it did not include the most critically ill children as they were too
unstable at admission to request consent, died before sample
collection was possible or were excluded by the study protocol.
This group also had higher admission temperatures, septicaemia
rates and mortality and is thus likely to receive the most benefit
from antimicrobial treatment. Paradoxically, this group is also
at greatest risk of renal compromise and potential gentamicin
toxicity. Information on the pharmacokinetics of gentamicin in
this group is now needed.
Current evidence favours the use of extended interval genta-
micin dosing in children.16 However, in contrast to the adult
population, where dosage adjustment guidelines and nomograms
are available,17,18 there is limited information on the influence of
clinical factors on drug dosing requirements in this patient popu-
lation. Additionally, the impact of intramuscular administration
(the only feasible option in this clinical setting described in the
present study) on absorption and peak concentrations is unclear.
A previous study19 identified a wide variability in gentamicin
concentrations observed 1 h after an intramuscular injection of














































































































































































Figure 3. Measured gentamicin concentrations plotted against predicted concentrations obtained from the population pharmacokinetic model parameter
estimates (left-hand panel) and predicted concentrations obtained from the individual pharmacokinetic parameter estimates (right-hand panel). The numbers
represent individual patients and the solid lines are the lines of identity.
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8 mg/kg to 107 infants aged 0–99 days. Although fewer patients
contributed to the present study, rapid absorption from the intra-
muscular site was observed (Figure 1). Tighter control of drug
administration and sampling may have contributed to this obser-
vation. Rapid absorption was also identified in another paediatric
study (n ¼ 10) in which concentrations averaging 7.2 mg/L were
observed at 15 min and 8.9 mg/L at 30 min after a lower intra-
muscular dose of 4 mg/kg.20 It was not possible to determine
bioavailability in the present study since all doses were given
intramuscularly, but the measured concentrations were high
enough to suggest that absorption was not compromised by the
intramuscular route.
Previous studies in infants and children given iv
gentamicin have found estimates of volume of distribution to be
0.3–0.5 L/kg.21 – 24 Higher estimates were obtained in the
current study with a mean (SD) Vss/F of 0.67 (0.22) L/kg and
ranged 0.26–1.31 L/kg. Although the use of a two-compartment
model and differences in the route of administration may have
influenced these results, it is likely that malnutrition and sepsis
also contributed. A 14% increase in the volume of distribution
in septic neonates was reported by Lingvall et al.,25 and in the
present study, elevations of bicarbonate concentration and the
derived factor, base deficit, were associated with an increased
volume of distribution. Both the use of parenteral nutrition and
clinical indicators of malnutrition have been associated with an
increased gentamicin volume of distribution in adults,26,27 but
Samotra et al.20 found no significant differences in gentamicin
pharmacokinetics between malnourished and normal children
given 4 mg/kg intramuscularly. However, their study only com-
prised 10 patients and both the age range (4–14 years) and the
interpatient variability were wide. In contrast, Bravo et al.28
administered a single iv dose of 3.5 mg/kg and identified lower
gentamicin peaks and a higher volume of distribution (0.46 L/kg
compared with 0.39 L/kg) in 11 malnourished infants with
marasmus when compared with 7 eutrophic infants. The present
study identified not only a higher value for apparent volume of
distribution in severely malnourished children but also a wide
range between patients. Higher values of base deficit were
associated with larger values of volume of distribution and
although a trend was also found with the presence of oedema,
there were insufficient data to characterize the effect. A larger
patient group would be required to investigate this further.
Nevertheless, the recommended dose of 7.5 mg/kg achieved
peak concentrations in the range associated with efficacy in the
majority of patients.
The second factor to be considered is whether the dosage
interval of 24 h is appropriate for all patients. Only 1 of 34
patients from subgroups tested on day 1, day 3 or day 5 (Groups
A, B and C) had a trough concentration above 1 mg/L. This
patient (number 34) developed renal failure and subsequently
died. As expected, weight and serum creatinine concentration
were the most important predictors of gentamicin clearance, but
other factors such as low temperature, base deficit, prolonged
CRT (markers of hypovolaemic shock) and oedema were also
associated with low clearance values. Only temperature and base
deficit achieved statistical significance, possibly due to the low
patient numbers that were included and Patient 34, who was
particularly unwell, was particularly influential in the model
development. Buchanan et al.29 noted a prolonged elimination
of gentamicin in the acute phase of kwashiorkor, which they
attributed to a reduction in glomerular filtration rate and which
resolved following treatment. This suggests that the day of
sampling and other therapy may also have influenced the results.
Due to the sampling times used in this study and the profile
obtained, the initial half-lives of 1.5 h probably represent a
mixture of distribution and elimination, whereas the apparent
elimination half-lives of 15 h partially reflect the very slow
terminal elimination phase. Similar results have been observed
previously in gentamicin population studies in adults.30,31 The
slow terminal elimination of gentamicin normally only contrib-
utes a small proportion of the overall exposure and is often
ignored for clinical purposes. However, a particularly slow elim-
ination was observed in Patient 34, and, if therapy had contin-
ued, a dosage interval of 60–72 h would have been more
appropriate for this individual. The current WHO guidelines rec-
ommend that the second dose of gentamicin should be withheld
until the child is passing urine.11 Current data support this con-
clusion, but further exploration of this group is warranted given
the concern of the potential toxicity of the 24 h interval dosing
in this group.
Conclusions
In an environment where routine analysis of gentamicin concen-
trations is not feasible, a population pharmacokinetic analysis
can provide useful information on the clinical characteristics
that might lead to underdosing or overdosing. Although further
work is required to identify appropriate dosage regimens for
patients with severe renal impairment or shock, this study has
demonstrated that satisfactory gentamicin peak and trough con-
centrations are achieved in the majority of malnourished children
who are given a single daily intramuscular dose of 7.5 mg/kg.
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